Feature Channels:

Clinical Trials

Add to Favorites Subscribe Share
fbshare-Clinical Trials

Showing results

110 of 71
Newswise: Researchers identify traits linked to better outcomes in HPV-linked head and neck cancer

Article ID: 714400

Researchers identify traits linked to better outcomes in HPV-linked head and neck cancer

University of North Carolina Health Care System

University of North Carolina Lineberger Comprehensive Cancer Center researchers identified characteristics that could be used to personalize treatment for patients with a type of head and neck cancer linked to HPV infection.

Released:
14-Jun-2019 3:05 PM EDT
JOS-logo.gif

Article ID: 714245

Genetic marker linked to increased risk of diabetic peripheral neuropathy

Joslin Diabetes Center

BOSTON – (June 11, 2019) – Researchers from Joslin Diabetes Center, using a genome-wide association study, have identified a genetic factor linked to the development of diabetic peripheral neuropathy. This finding suggests a new target for preventive therapies. The research has been published online and will appear in the August print issue of Diabetes.

Released:
11-Jun-2019 2:05 PM EDT
Newswise: Quatre millions de dollars pour le criblage de médicaments

Article ID: 714234

Quatre millions de dollars pour le criblage de médicaments

The Neuro - Montreal Neurological Institute and Hospital

L’Institut et hôpital neurologiques de Montréal (le Neuro) dirigera un partenariat en science ouverte en vue de la mise au point de médicaments de précision indiqués dans la sclérose latérale amyotrophique (SLA) et la maladie de Parkinson (MP).

Released:
11-Jun-2019 1:05 PM EDT
Newswise: $4M for open science drug screening

Article ID: 714233

$4M for open science drug screening

The Neuro - Montreal Neurological Institute and Hospital

The Neuro (Montreal Neurological Institute and Hospital) will lead an open science partnership to develop precision drugs for amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD).

Released:
11-Jun-2019 12:05 PM EDT
release banner.jpg
  • Embargo expired:
    11-Jun-2019 11:15 AM EDT

Article ID: 713681

Eating More Vitamin K Found to Help, Not Harm, Patients on Warfarin

American Society for Nutrition (ASN)

When prescribed the anticoagulant drug warfarin, many patients are told to limit foods rich in vitamin K, such as green vegetables. The results of a new clinical trial call that advice into question and suggest patients on warfarin actually benefit from increasing their vitamin K intake—as long as they keep their intake levels consistent.

Released:
3-Jun-2019 9:00 AM EDT

Article ID: 714158

AMP Bolsters Position on Consumer Genomic Testing

Association for Molecular Pathology

AMP has revised its official position for all consumer genomic testing. Based on a recent assessment of the current market landscape and privacy best practices, the latest position statement features an expanded list of conditions that must be met before AMP can support a clinically-meaningful test.

Released:
10-Jun-2019 11:05 AM EDT

Channels:

Clinical Trials, Genetics

Languages:

English

Newswise: Large international study finds diabetes drug cuts cardiovascular and kidney problems
  • Embargo expired:
    9-Jun-2019 7:30 PM EDT

Article ID: 714034

Large international study finds diabetes drug cuts cardiovascular and kidney problems

McMaster University

A clinical trial that followed more than 9,900 people in 24 countries has found that the drug dulaglutide reduced cardiovascular events and kidney problems in middle-aged and older people with Type 2 diabetes. During more than five years of follow-up, cardiovascular events like heart attacks and strokes were reduced by 12% in people taking dulaglutide compared to people taking a placebo. This effect was seen in both men and women with or without previous cardiovascular disease.

Released:
6-Jun-2019 12:05 PM EDT
Newswise: Lymphoma trial finds combination targeted therapy effective prior to chemotherapy
  • Embargo expired:
    4-Jun-2019 1:10 PM EDT

Article ID: 713853

Lymphoma trial finds combination targeted therapy effective prior to chemotherapy

University of Texas M. D. Anderson Cancer Center

Results of a Phase II clinical trial conducted at The University of Texas MD Anderson Cancer Center revealed that combination targeted therapy, consisting of rituximab, lenalidomide and ibrutinib (RLI), had an 84.6 percent overall response rate (ORR) and 38.5 percent complete response rate (CRR) when given prior to any chemotherapy for newly diagnosed patients with a specific type of diffuse large b-cell lymphoma (DLBCL).

Released:
3-Jun-2019 2:05 PM EDT
uclahealthlogo.gif
  • Embargo expired:
    3-Jun-2019 10:45 AM EDT

Article ID: 713648

Traditional chemotherapy still gold standard over new targeted therapy for HER2-positive breast cancers

University of California, Los Angeles (UCLA), Health Sciences

Results of a phase 3 clinical trial by researchers at UCLA’s Jonsson Comprehensive Cancer Center found that women with HER2-positive breast cancer had significantly better response rates, but more severe side effects, when they were treated with traditional neoadjuvant chemotherapy along with dual HER2-targeted blockade, compared to a more novel approach using HER2-targeted chemotherapy plus HER2-targeted blockade.

Released:
3-Jun-2019 10:45 AM EDT

Showing results

110 of 71

Chat now!